These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18631118)

  • 1. Tuberculosis: a balanced diet of lipids and carbohydrates.
    Bhowruth V; Alderwick LJ; Brown AK; Bhatt A; Besra GS
    Biochem Soc Trans; 2008 Aug; 36(Pt 4):555-65. PubMed ID: 18631118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure, function and biosynthesis of the Mycobacterium tuberculosis cell wall: arabinogalactan and lipoarabinomannan assembly with a view to discovering new drug targets.
    Alderwick LJ; Birch HL; Mishra AK; Eggeling L; Besra GS
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1325-8. PubMed ID: 17956343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arabinogalactan and lipoarabinomannan biosynthesis: structure, biogenesis and their potential as drug targets.
    Jankute M; Grover S; Rana AK; Besra GS
    Future Microbiol; 2012 Jan; 7(1):129-47. PubMed ID: 22191451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promising drugs against tuberculosis.
    de Souza MV
    Recent Pat Antiinfect Drug Discov; 2006 Jan; 1(1):33-44. PubMed ID: 18221132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting Anti-tuberculosis Therapeutic Strategies That Target the Peptidoglycan Structure and Synthesis.
    Catalão MJ; Filipe SR; Pimentel M
    Front Microbiol; 2019; 10():190. PubMed ID: 30804921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review on Benzimidazole Scaffolds as Inhibitors of
    Bhaskar V; Kumar S; Nair AS; Rajappan KP; Sudevan ST; Parambi DGT; Al-Sehemi AG; Zachariah SM; Pappachen LK
    Comb Chem High Throughput Screen; 2023; 26(4):668-681. PubMed ID: 35430964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assembly of the Mycobacterial Cell Wall.
    Jankute M; Cox JA; Harrison J; Besra GS
    Annu Rev Microbiol; 2015; 69():405-23. PubMed ID: 26488279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell Surface Biosynthesis and Remodeling Pathways in Mycobacteria Reveal New Drug Targets.
    Shaku M; Ealand C; Kana BD
    Front Cell Infect Microbiol; 2020; 10():603382. PubMed ID: 33282752
    [No Abstract]   [Full Text] [Related]  

  • 10. Emerging therapeutic targets in tuberculosis: post-genomic era.
    Khasnobis S; Escuyer VE; Chatterjee D
    Expert Opin Ther Targets; 2002 Feb; 6(1):21-40. PubMed ID: 11901479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent updates on drug resistance in Mycobacterium tuberculosis.
    Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
    J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug-resistant to extensively drug resistant tuberculosis: what is next?
    Jain A; Dixit P
    J Biosci; 2008 Nov; 33(4):605-16. PubMed ID: 19208985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
    de Wet TJ; Warner DF; Mizrahi V
    Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress on mechanism of ethambutol resistance in Mycobacterium Tuberculosis.
    Wang T; Jiao WW; Shen AD
    Yi Chuan; 2016 Oct; 38(10):910-917. PubMed ID: 27806932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of embCAB mutations associated with ethambutol resistance in multidrug-resistant mycobacterium tuberculosis isolates from China.
    Zhao LL; Sun Q; Liu HC; Wu XC; Xiao TY; Zhao XQ; Li GL; Jiang Y; Zeng CY; Wan KL
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2045-50. PubMed ID: 25605360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure of mycobacteria to cell wall-inhibitory drugs decreases production of arabinoglycerolipid related to Mycolyl-arabinogalactan-peptidoglycan metabolism.
    Rombouts Y; Brust B; Ojha AK; Maes E; Coddeville B; Elass-Rochard E; Kremer L; Guerardel Y
    J Biol Chem; 2012 Mar; 287(14):11060-9. PubMed ID: 22315220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xpert
    Kohli M; Schiller I; Dendukuri N; Dheda K; Denkinger CM; Schumacher SG; Steingart KR
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012768. PubMed ID: 30148542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Mycobacterial Cell Wall--Peptidoglycan and Arabinogalactan.
    Alderwick LJ; Harrison J; Lloyd GS; Birch HL
    Cold Spring Harb Perspect Med; 2015 Mar; 5(8):a021113. PubMed ID: 25818664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.